Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the melanoma genetics consortium

Journal of Clinical Oncology

Volumn 17, Issue 10, 1999, Pages 3245-3251

  Kefford, Richard F ^a   Newton Bishop, Julia A ^a   Bergman, Wilma ^a   Tucker, Margaret A ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER EPIDEMIOLOGY; CANCER SCREENING; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; COUNSELING; FAMILY HISTORY; GENETIC COUNSELING; GENETIC SUSCEPTIBILITY; HUMAN; MELANOMA; PRIORITY JOURNAL;

EID: 0032887878     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.10.3245     Document Type: Article

References (52)

1. Goldstein AM, Fraser MC, Struewing JP, et al: Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 333:970-974, 1995
2. Goldstein AM, Tucker MA: Genetic epidemiology of familial melanoma. Dermatol Clin 13:605-612, 1995
3. Tucker MA, Boice JD Jr, Hoffman DA: Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Connecticut, 1935-82. Natl Cancer Inst Monogr 68:161-189, 1985
4. Ford D, Bliss JM, Swerdlow AJ, et al: Risk of cutaneous melanoma associated with a family history of the disease: The International Melanoma Analysis Group (IMAGE). Int J Cancer 62:377-381, 1995
5. Marrett LD, King WD, Walter SD, et al: Use of host factors to identify people at high risk for cutaneous malignant melanoma. Can Med Assoc J 147:445-453, 1992
6. Bliss JM, Ford D, Swerdlow AJ, et al: Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: Systematic overview of 10 case-control studies - The International Melanoma Analysis Group (IMAGE). Int J Cancer 62:367-376, 1995
7. Newton JA, Bataille V, Griffiths K, et al: How common is the atypical mole syndrome phenotype in apparently sporadic melanoma? J Am Acad Dermatol 29:989-996, 1993
8. Grulich AE, Bataille V, Swerdlow AJ, et al: Naevi and pigmentary characteristics as risk factors for melanoma in a high-risk population: A case-control study in New South Wales, Australia. Int J Cancer 67:485-491, 1996
9. Tucker MA, Halpern A, Holly EA, et al: Clinically recognized dysplastic nevi: A central risk factor for cutaneous melanoma. JAMA 277:1439-1444, 1997
10. Zhang Y, Xiong Y, Yarbrough WG: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-734, 1998
11. Pomerantz J, Schreiber-Agus N, Liegeois NJ, et al: The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723, 1998
12. Kamijo T, Zindy F, Roussel MF, et al: Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91:649-659, 1997
13. Goldstein AM, Tucker MA: Screening for CDKN2A mutations in hereditary melanoma. J Natl Cancer Inst 89:676-678, 1997 (editorial)
14. Zuo L, Weger J, Yang Q, et al: Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12:97-99, 1996
15. Soufir N, Avril MF, Chompret A, et al: Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. Hum Mol Genet 7:209-16, 1998
16. Hayward NK: The current situation with regard to human melanoma and genetic inferences. Curr Opin Oncol 8:136-142, 1996
17. Liu L, Dilworth D, Gao L, et al: Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet 21:128-132, 1999
18. Battistutta D, Palmer J, Walters M, et al: Incidence of familial melanoma and MLM2 gene. Lancet 344:1607-1608, 1994
19. Cannon-Albright LA, Meyer LJ, Goldgar DE, et al: Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM). Cancer Res 54:6041-6044, 1994
20. Goldstein AM, Falk RT, Fraser MC, et al. Sun-related risk factors in melanoma-prone families with CDKN2A mutations. J Natl Cancer Inst 90:709-711, 1998
21. Tucker MA, Fraser MC, Goldstein AM, et al: The risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol 100:350S-355S, 1993
22. Bale SJ, Chakravarti A, Greene MH: Cutaneous malignant melanoma and familial dysplastic nevi: Evidence for autosomal dominance and pleiotropy. Am J Hum Genet 38:188-196, 1986
23. Moll AC, Imhof SM, Bouter LM, et al: Second primary tumors in patients with retinoblastoma: A review of the literature. Ophthalmic Genet 18:27-34, 1997
24. Eeles RA: Germline mutations in the TP53 gene. Cancer Surv 25:101-124, 1995
25. Elder DE: Human melanocytic neoplasms and their etiologic relationship with sunlight. J Invest Dermatol 92:297S-303S, 1989
26. English JS, Swerdlow AJ: The risk of malignant melanoma, internal malignancy and mortality in xeroderma pigmentosum patients. Br J Dermatol 117:457-461, 1987
27. Goto M, Miller RW, Ishikawa Y, et al: Excess of rare cancers in Werner syndrome (adult progeria). Cancer Epidemiol Biomarkers Prev 5:239-246, 1996
28. Barnett JH, Lee FG, Rinsky MJ: Acral lentiginous melanoma and lentigo maligna occurring in Werner's syndrome. Cutis 32:277-279, 283, 1983
29. Monzon J, Liu L, Brill H, et al: CDKN2A mutations in multiple primary melanomas. N Engl J Med 338:879-887, 1998
30. Goldstein AM, Fraser MC, Clark WH Jr, et al: Age at diagnosis and transmission of invasive melanoma in 23 families with cutaneous malignant melanoma/dysplastic nevi. J Natl Cancer Inst 86:1385-1390, 1994
31. Salmon JA, Rivers JK, Donald JA, et al: Clinical aspects of hereditary melanoma in Australia. Cytogenet Cell Genet 59:170-172, 1992
32. Gruis NA, Sandkuijl LA, van der Velden PA, et al: CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families. Melanoma Res 5:169-177, 1995
33. Ranade K, Hussussian CJ, Sirkosi RS, et al: Mutations associated with familial melanoma impair p16INK4 function. Nat Genet 10:114-116, 1995
34. Wachsmuth RC, Harland M, Bishop JA: The atypical-mole syndrome and predisposition to melanoma. N Engl J Med 339:348-349, 1998 (letter)
35. Holland EA, Beaton SC, Becker TM, et al: Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene 11:2289-2294, 1995
36. Tibben A, Vegter-van der Vlis M, Skraastad MI, et al: DNA-testing for Huntington's disease in the Netherlands: A retrospective study on psychosocial effects. Am J Med Genet 44:94-99, 1992
37. Holland EA, Schmid H, Kefford RF, et al: CDKN2A (p16INK4a) and CDK4 mutation analysis in 131 Australian melanoma probands: Effect of family history and multiple primary melanomas. Genes Chromosom Cancer 25:1-10, 1999
38. National Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma, January 27-29, 1992. Am J Dermatopathol 15:34-43, discussion 46-51, 1993
39. Slade J, Marghoob AA, Salopek TG, et al: Atypical mole syndrome: Risk factor for cutaneous malignant melanoma and implications for management. J Am Acad Dermatol 32:479-494, 1995
40. Ferrini RL, Perlman M, Hill L: American College of Preventive Medicine practice policy statement: Skin protection from ultraviolet light exposure - The American College of Preventive Medicine. Am J Prev Med 14:83-86, 1998
41. Gasparro FP, Mitchnick M, Nash JF: A review of sunscreen safety and efficacy. Photochem Photobiol 68:243-256, 1998
42. Setlow RB, Grist E, Thompson K, et al: Wavelengths effective in induction of malignant melanoma. Proc Natl Acad Sci U S A 90:6666-6670, 1993
43. Krien PM, Moyal D: Sunscreens with broad-spectrum absorption decrease the trans to cis photoisomerization of urocanic acid in the human stratum corneum after multiple UV light exposures. Photochem Photobiol 60:280-287, 1994
44. McGovern TW, Litaker MS: Clinical predictors of malignant pigmented lesions: A comparison of the Glasgow seven-point checklist and the American Cancer Society's ABCDs of pigmented lesions. J Dermatol Surg Oncol 18:22-26, 1992
45. Kenet RO, Kang S, Kenet BJ, et al: Clinical diagnosis of pigmented lesions using digital epiluminescence microscopy: Grading protocol and atlas. Arch Dermatol 129:157-174, 1993
46. Menzies SW, Ingvar C, McCarthy WH: A sensitivity and specificity analysis of the surface microscopy features of invasive melanoma. Melanoma Res 6:55-62, 1996
47. Kelly JW, Yeatman JM, Regalia C, et al: A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance. Med J Aust 167:191-194, 1997
48. Hille ET, van Duijn E, Gruis NA, et al: Excess cancer mortality in six Dutch pedigrees with the familial atypical multiple mole-melanoma syndrome from 1830 to 1994. J Invest Dermatol 110:788-792, 1998
49. Nitecki SS, Sarr MG, Colby TV, et al: Long-term survival after resection for ductal adenocarcinoma of the pancreas: Is it really improving? Ann Surg 221:59-66, 1995
50. Stevens PD, Lightdale CJ: The role of endosonography in the diagnosis and management of pancreatic cancer. Surg Oncol Clin North Am 7:125-133, 1998
51. Friess H, Langhans J, Ebert M, et al: Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut 36:771-777, 1995
52. American Society of Clinical Oncology: Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility. J Clin Oncol 14:1730-1740, 1996